+437.1%
GDX vs MRNA
+516.4%
-79.3%
-49.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.1% | -3.4% | +4.4% | +1.3% |
| 7D | +1.9% | -10.1% | +12.0% | +2.6% |
| 30D | +9.9% | +126.7% | -116.8% | -0.7% |
| 3M | +28.2% | +184.1% | -155.9% | +13.9% |
| 6M | -2.9% | +143.3% | -146.2% | -13.0% |
| YTD | +16.0% | +359.9% | -343.9% | 0.0% |
| 1Y | +49.9% | +454.2% | -404.3% | +27.7% |
| 3Y | +263.6% | +26.0% | +237.6% | +227.8% |
| 5Y | +233.6% | -70.3% | +303.8% | +214.2% |
| All | +437.1% | +516.4% | -79.3% | +327.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling